Volume 16 - Special Issue on Cognitive Sciences- In Press
BCN 2025, 16 - Special Issue on Cognitive Sciences- In Press: 233-250 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zarei S, Shalbaf R, Shalbaf A. Statistical Method for Identification of Alzheimer Disease With Multimodal Predictive Markers Mild Cognitive Impairment. BCN 2025; 16 (S1) :233-250
URL: http://bcn.iums.ac.ir/article-1-2919-en.html
URL: http://bcn.iums.ac.ir/article-1-2919-en.html
1- Institute for Cognitive Science Studies, Tehran, Iran.
2- Department of Biomedical Engineering and Medical Physics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Department of Biomedical Engineering and Medical Physics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: Predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is crucial for early intervention. Identifying reliable predictive markers can enhance diagnostic accuracy and improve clinical decision-making. This study aimed to explore multimodal predictive markers to distinguish stable MCI (sMCI) from progressive MCI (pMCI) to AD using statistical analysis.
Methods: We analyzed data from the Alzheimer's disease neuroimaging initiative (ADNI), categorizing 487 individuals as sMCI and 348 as pMCI. The study incorporated multiple assessment modalities, including demographics, positron emission tomography (PET), genotyping, magnetic resonance imaging (MRI), and neurocognitive tests. A rigorous data preprocessing approach was applied, including cleaning and feature selection. The area under the curve (AUC) and the Wilcoxon test were used to evaluate the discriminative power of predictive markers.
Results: Our findings showed the strong predictive potential of PET, particularly florbetaben (FBB), which achieved an AUC of 0.84. Neurocognitive tests, including the Alzheimer’s disease assessment scale (ADAS13), ADNI-modified preclinical Alzheimer cognitive composite (mPACCtrailsB and mPACCdigit), logical memory delayed recall total (LDELTOTAL), and ADAS cognitive subscale question 4 (ADASQ4), also demonstrated high discriminatory power with AUC values ranging from 0.82 to 0.83. These results indicated that a combination of neuroimaging and cognitive assessments can significantly differentiate between sMCI and pMCI.
Conclusion: The results emphasize the importance of multimodal assessments, particularly PET imaging and neurocognitive tests, in distinguishing sMCI from pMCI. These findings contribute to early AD diagnosis strategies and personalized intervention planning.
Methods: We analyzed data from the Alzheimer's disease neuroimaging initiative (ADNI), categorizing 487 individuals as sMCI and 348 as pMCI. The study incorporated multiple assessment modalities, including demographics, positron emission tomography (PET), genotyping, magnetic resonance imaging (MRI), and neurocognitive tests. A rigorous data preprocessing approach was applied, including cleaning and feature selection. The area under the curve (AUC) and the Wilcoxon test were used to evaluate the discriminative power of predictive markers.
Results: Our findings showed the strong predictive potential of PET, particularly florbetaben (FBB), which achieved an AUC of 0.84. Neurocognitive tests, including the Alzheimer’s disease assessment scale (ADAS13), ADNI-modified preclinical Alzheimer cognitive composite (mPACCtrailsB and mPACCdigit), logical memory delayed recall total (LDELTOTAL), and ADAS cognitive subscale question 4 (ADASQ4), also demonstrated high discriminatory power with AUC values ranging from 0.82 to 0.83. These results indicated that a combination of neuroimaging and cognitive assessments can significantly differentiate between sMCI and pMCI.
Conclusion: The results emphasize the importance of multimodal assessments, particularly PET imaging and neurocognitive tests, in distinguishing sMCI from pMCI. These findings contribute to early AD diagnosis strategies and personalized intervention planning.
Type of Study: Original |
Subject:
Cognitive Neuroscience
Received: 2024/04/20 | Accepted: 2024/10/26 | Published: 2025/03/18
Received: 2024/04/20 | Accepted: 2024/10/26 | Published: 2025/03/18
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
